Table 2
Cytokine and ICAM-1 genotype frequencies in patients with CP and controls
| Genotype | CP patients N (%) | Controls N (%) | p Value* | OR (95% CI) |
|---|---|---|---|---|
| All p values were non-significant. | ||||
| *Uncorrected p value, corrected p value is ×10 uncorrected value; †non-significant trend (p = 0.05–0.1). | ||||
| CI, confidence interval; CP, chronic pancreatitis; ICAM-1, intercellular cell adhesion molecule 1; IL, interleukin; OR, odds ratio; TGFβ1, transforming growth factor β1; TNFα, tumour necrosis factor α; VEGF, vascular endothelial growth factor. | ||||
| IL-1β −35 | ||||
| CC | 11 (21.2) | 22 (13.4) | 0.26 | 1.73 (0.79 to 3.82) |
| CT | 25 (48.1) | 76 (46.3) | 0.95 | 1.07 (0.58 to 1.99) |
| TT | 16 (30.8) | 66 (40.2) | 0.29 | 0.66 (0.34 to 1.28) |
| N = 52 | N = 164 | |||
| IL-1β −511 | ||||
| CC | 17 (34.0) | 87 (33.0) | 1.00 | 1.03 (0.55 to 1.94) |
| CT | 25 (50.0) | 135 (51.7) | 0.95 | 0.93 (0.51 to 1.70) |
| TT | 8 (16.0) | 39 (14.9) | 1.00 | 1.08 (0.48 to 2.45) |
| N = 50 | N = 261 | |||
| IL-6 −174 | ||||
| GG | 18 (34.6) | 79 (35.3) | 1.00 | 0.93 (0.52 to 1.82) |
| GC | 25 (48.1) | 101 (45.1) | 0.81 | 1.13 (0.62 to 2.05) |
| CC | 9 (17.3) | 44 (19.6) | 0.85 | 0.86 (0.40 to 1.86) |
| N = 52 | N = 224 | |||
| IL-8 −251 | ||||
| AA | 6 (11.5) | 54 (22.9) | 0.10† | 0.44 (0.18 to 1.06) |
| AT | 28 (53.9) | 105 (44.7) | 0.30 | 1.44 (0.79 to 2.63) |
| TT | 18 (34.6) | 76 (32.3) | 0.88 | 1.11 (0.59 to 2.08) |
| N = 52 | N = 235 | |||
| TNFα −308 | ||||
| GG | 38 (76.0) | 146 (68.2) | 0.37 | 1.48 (0.73 to 2.97) |
| GA | 11 (22.0) | 56 (26.2) | 0.67 | 0.80 (0.39 to 1.64) |
| AA | 1 (2.0) | 12 (5.6) | 0.47 | 0.34 (0.04 to 2.71) |
| N = 50 | N = 214 | |||
| TGFβ1 +915 | ||||
| GG | 44 (88.6) | 133 (83.1) | 0.97 | 1.12 (0.48 to 2.59) |
| GC | 6 (11.5) | 26 (16.3) | 0.55 | 0.67 (0.27 to 1.70) |
| CC | 2 (4.2) | 1 (0.6) | 0.17 | 6.36 (0.56 to 71.63) |
| N = 52 | N = 160 | |||
| VEGF −2578 | ||||
| CC | 15 (30.6) | 82 (30.8) | 1.00 | 0.99 (0.52 to 1.90) |
| AC | 19 (38.8) | 115 (43.2) | 0.67 | 0.83 (0.45 to 1.54) |
| AA | 15 (30.6) | 69 (25.9) | 0.61 | 1.26 (0.65 to 2.44) |
| N = 49 | N = 266 | |||
| VEGF −1154 | ||||
| GG | 21 (42.0) | 120 (45.6) | 0.75 | 0.86 (0.47 to 1.58) |
| GA | 20 (40.0) | 109 (41.4) | 0.97 | 0.94 (0.51 to 1.74) |
| AA | 9 (18.0) | 34 (12.9) | 0.47 | 1.48 (0.67 to 3.27) |
| N = 50 | N = 263 | |||
| ICAM-1+241 | ||||
| GG | 41 (85.4) | 210 (81.7) | 0.90 | 1.15 (0.51 to 2.60) |
| GA | 8 (19.5) | 40 (15.6) | 1.00 | 1.06 (0.47 to 2.39) |
| AA | 0 (0.0) | 7 (2.7) | 0.60 | 0.00 (0.00 to 2.86) |
| N = 49 | N = 257 | |||
| ICAM-1+469 | ||||
| GG | 5 (11.9) | 48 (21.4) | 0.24 | 0.50 (0.19 to 1.31) |
| GA | 27 (64.3) | 109 (48.7) | 0.08† | 1.93 (0.98 to 3.79) |
| AA | 10 (23.8) | 69 (29.9) | 0.49 | 0.71 (0.34 to 1.51) |
| N = 42 | N = 226 | |||
